ID: MRFR/MED/4680-CR | January 2021 | Region: Global | 164 pages
Global Urinary Tract Infections Market was valued at USD 9,490.88 Million in 2019 and is expected to register a CAGR of 3.62% during the forecast period of 2020 to 2027.
A urinary tract infection (UTI) is an infection in any part of the urinary system such as kidneys, ureters, bladder, and urethra. UTIs can be caused due to various reasons, including unsafe sex, lack of hygiene, and diabetes. UTIs are more common in women than men due to inherent complications in the female reproductive system. According to the World Health Organization, 1 million hospitalizations of women occur each year due to UTIs, which affect almost half the female population around the world.
Diabetes and urological health issues are closely connected. Diabetes result in UTIs and bladder issues. It can often make urologic conditions even worse because it can impact blood flow, nerves, and sensory functions in the body. A large population of the world is affected by diabetes. According to the International Diabetes Federation, approximately 463 million adults (20–79 years) were living with diabetes in 2019, and this will rise to 700 million by 2045. It added that 79% of adults with diabetes were living in low- and middle-income countries in 2019. With the increasing prevalence of diabetes and kidney stones, the number of cases of UTI increases, which increases the demand for drugs, thus, driving the global urinary tract infection market. Rise in research & development (R&D) of a novel class of antibiotics for urinary tract infections is also expected to aid the growth of the market. In August 2017, the FDA approved a new antibiotic combination drug for the treatment of patients with cUTI. The drug, Vabomere, contains the antibiotic meropenem and the novel beta-lactamase inhibitor vaborbactam. In its press release, FDA stated that Vabomere demonstrated statistical superiority over another antibiotic/beta-lactamase combination drug in a multi-center, randomized phase 3 clinical trial of 545 cUTI patients, including those with acute pyelonephritis (kidney infection). This launch of more efficient combination drugs is expected to boost the growth of the urinary tract infection market.
However, complex regulatory requirements are expected to hinder the growth of the global urinary tract infection market. The clinical trial of an antibiotic differs from other therapeutic drugs with respect to the clinical approval approach, such as clinical trial design, interpretation, and analysis. The sponsor must conduct non-inferiority trials to get the approval along with currently registered antibacterial drugs. The clinical trials for designing antibacterial drugs are complex and require an informative, ethical, and scientific approach. These factors are expected to restrain market growth during the forecast period.
Global Urinary Tract Infections Market Share, By Type, 2019 (%)
Source: MRFR Analysis
Global Urinary Tract Infections Market has been divided based on Drug Class, Application, Pathogen, End User.
The market, based on drug class, has been segmented into quinolones, β-lactam & cephalosporins, aminoglycosides, penicillin, and azoles. The quinolones are further sub-segmented into ciprofloxacin, enoxacin, norfloxacin, ofloxacin, pefloxacin, and fleroxacin. The cephalosporin is divided into avycaz, cedax, cefdinir, and cefditoren. β-lactam is further segmented into amoxicillin-clavulanate, cefdinir, cefaclor, and cefpodoxime-proxetil. The quinolones segment accounted for the largest market share of 41.57% in 2019.
The market, based on application, has been bifurcated into urethritis, cystitis, and pyelonephritis. The treatment segment dominated the global urinary tract infections market in 2019. The urethritis segment accounted for the largest market share in 2019. The market, based on pathogen, has been bifurcated into Escherichia coli, Staphylococcus saprophyticus, Klebsiella pneumoniae, Proteus mirabilis, and Enterococcus faecalis. The Escherichia coli segment accounted for the largest market share of 65.59% in 2019. On the basis of end user, the global urinary tract infections market has been classified as hospitals, clinics, self-administered, and others. The hospitals segment accounted for the largest market share in 2019. This is because hospitals provide patients all types of treatment and diagnostic options and consultations in a single visit. The market growth of this segment is due to the increasing number of hospitals and the rising number of urinary disorders such as interstitial cystitis and hematuria.
Global Urinary Tract Infections Market Share, By Region, 2019 (%)
Source: MRFR Analysis
The global UTI market, on the basis of region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. In 2019, the Americas accounted for the largest share of 33.6% of the global market. This large share is majorly attributed to the presence of key manufacturers, the rising prevalence of urinary tract infections, and the growing aging woman population in the region. The market in the Americas is majorly divided into North America and Latin America. The North American market includes the US and Canada. The Americas dominate the global market owing to the rising technological advancements in diagnostics and therapeutic products coupled with the rising prevalence of urinary tract diseases and other kidney problems. The US is the leading country with the largest share in the UTI market. Europe is the second-largest regional market in terms of revenue. Urinary disorders account for a tremendous economic burden in Europe. The high-income countries, the EU5 (France, Germany, Italy, Spain, and the UK), typically spend 2–3% of their annual health budget on the treatment of urinary disease as per a bulletin published by the WHO. The factors responsible for market growth in this region are rising awareness of urinary tract diseases, increasing educational activity, and the availability of different diagnostic and therapeutic methods to manage the infection.
Asia-Pacific is expected to be the fastest-growing market for UTI during the forecast period. This can be attributed to the developing economies and highly populated countries such as China, India, and South Korea. The Asia-Pacific region is expected to accomplish the most elevated development in the global market during the forecast period owing to the presence of a large number of drug manufacturing companies, rising patient population, and growing awareness about the treatment for a urinary health condition. Furthermore, increasing demand for UTI diagnosis and treatment methods in private hospitals and clinics also acts as an opportunity for the market to flourish in this region. The African market for UTI is growing and will continue to grow at a steady pace. The rapid urbanization in these countries has led to increased exposure to numerous environmental toxins, a highly infectious disease burden, and rising incidences of non-communicable diseases. The market in the Middle East & Africa was valued at USD 759.22 million in 2019 and anticipated to register a CAGR of 2.27% during the forecast period.
The Prominent Players in the Global Urinary Tract Infections Market are Pfizer Inc., Novo Nordisk A/S, Novartis Ag, Merck & Co., Inc., Eli Lily and Company, Allergan, Cipla Inc., Teva Pharmaceuticals, GlaxoSmithKline plc, and Bayer AG.
Global Urinary Tract Infections Market, By Type
Global Urinary Tract Infections Market, By Diagnosis & Treatment
Global Urinary Tract Infections Market, by End User
Global Urinary Tract Infections Market, By Region
Available Additional Customizations
Frequently Asked Questions (FAQ) :
The urinary tract infection (UTI) market would grow up to USD9.89 billion by 2023.
The urinary tract infection (UTI) market would grow with a 3.6% CAGR during the forecast period of 2018 to 2023.
North America would display strong market positioning among all the urinary tract infection (UTI) market players.
The US would trigger growth for the North American urinary tract infection (UTI) market.
The Asia Pacific would be the fastest in terms of growth among all the urinary tract infection (UTI) market players.